Biologics in uveitis: An update

Kowsigan Magesan¹, Amravi Shah², Jyotirmay Biswas³*

1-3* Department of Uvea, SankaraNethralaya, Chennai, Tamil Nadu, India

Abstract

‘Uveitis is’ the term used to describe inflammation of the uvea. It can be due to infective or non-infective agents. Most of the non-infectious uveitides are autoimmune or auto-inflammatory in nature, and the management of non-infective uveitis is often crucial. Advancements in biotechnology and understanding the pathophysiology of autoimmune diseases have enabled the development of the new class of drugs named ‘biologics’. These drugs act at cellular level inhibiting the actions of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-1, and IL-6, and B and T lymphocytes. Biologics have been proven to be less toxic and can be used in uveitic cases that are refractory to conventional therapy. Though the efficacy of biologics is based on insufficient clinical trials, majority of them indicate preferable outcomes on refractory uveitis, with remarkable promise to increase the possibility of long-term remission. In this review, we aimed to outline the ideal characteristics of each biologic drug and review the data to support the use of current and emerging biological therapies.

Keywords: Biologics, uveitis, cytokines, anti-TNF alpha, management

Introduction

Uveitis is a broad term to describe the inflammation of vascular coat of the eyeball. Anatomically, it can be classified as anterior, intermediate, posterior, and panuveitis (where all the layers of uvea are involved).¹ The prevalence of uveitis ranges from 38-284/100,000 in adults, but it is significantly lesser in children (28/100,000).² Despite the rarity, uveitis is the cause for legal visual impairment in about one third of the population.³ ⁴

Uveitis can be due to infectious agent or underlying systemic disease. In some cases, the underlying cause is not detected even after tailored laboratory investigations, and they are categorized as ‘idiopathic’.⁵ The first choice of treatment in idiopathic uveitis is corticosteroids.⁶ Long-term use of corticosteroids produced toxic effects both locally and systemically.⁶ ⁷ Corticosteroid-sparing immunomodulatory treatments were subsequently introduced to avoid such side effects. However, these therapies did not lead to suffice outcomes in some active uveitis cases or in the management of adverse effects.⁸ In order to circumvent this limitation, a new choice of drug named ‘biologics’ has been derived from living microorganisms, plants or animal cells.⁷ These agents target immune and inflammatory pathways at the cellular level thereby suppressing immune response and preventing further structural damage.⁹ Based on the target receptor, biologics can be classified into the following categories (Table 1):

1. TNF-α inhibitors
2. Anti-interleukin therapies
3. Interferons
4. Fusion protein of CTLA-4

1. TNF-α inhibitors

The cytokine TNF-α, a pro-inflammatory cytokine, plays a vital role in immune response to trauma or bacterial infections. TNF-α is produced by various cells including neutrophils and macrophages.⁶ ¹⁰ Increased level of TNF-α is noted in many autoimmune diseases and ocular inflammatory conditions. Studies have found increased concentrations of membrane-bound TNF-α and soluble TNF-α in aqueous humour during the disease activity.¹¹-¹⁴ Therefore, numerous targets have been identified, which act against TNF-α for the potential management of inflammation.

Adalimumab

It is a fully humanized monoclonal antibody directed against
TNF-α. It has been approved by FDA for the management of non-infectious uveitis. The drug has been approved in many cases of non-infectious uveitis. There are several studies suggesting the efficacy of adalimumab in the management of refractory uveitis. A multi-center study done by Jaffe et al. has found adalimumab to be associated with lowering uveitic inflammation and improving visual acuity in active non-infectious uveitis patients. Nguyen et al. have reported prolonged remission time with marked visual improvement in non-infectious uveitis cases treated with adalimumab. A study by Suhler et al. has noted that patients treated with adalimumab has sustained quiescence, without any increase in corticosteroid dose. A prospective study intended to find the efficacy of adalimumab in active ankylosing spondylitis (AS)-associated uveitis has noted a reduction in anterior chamber flare by 51%. Another study showed considerable amount of reduction in recurrences in AS-associated uveitis patients receiving adalimumab. In sarcoidosis patients, complete resolution of papillitis and improvement of cystoid macular edema (CME) had been achieved. Adalimumab showed significant improvement in visual acuity with the sustained remission of disease in a cohort with Behcet disease. A multicenter placebo-controlled study showed significantly lesser treatment failure in adalimumab arm in JRA-associated uveitis cases. Toxic effects of adalimumab should also be considered, despite its satisfactory results. The most common side effects are localized allergic reactions and headache. Severe side effects include malignancy, thrombolytic events, and congestive heart failure, and reactivation of tuberculosis (TB).

**Infliximab**

Infliximab is a chimeric monoclonal antibody, which neutralizes both soluble- and membrane-bound TNF-α. It has been proven to be effective in many non-uveitic conditions such as JIA-associated uveitis, sarcoidosis, birdshot chorioretinopathy, diffuse subretinal fibrosis, and sympathetic ophthalmia. Suhler et al. have achieved clinical success in 18 out of 23 patients with Behcet’s disease-associated uveitis. Markomichelakis et al. have compared the efficacy of infliximab and triamcinolone in reducing ocular inflammation. Better outcome results were noted in the group treated with infliximab, despite its side effects. In Japanese patients with Behcet's disease, there was improvement in disease status and mean visual acuity in 69%. However, half of the total population had adverse effects due to the infliximab. In a retrospective study of 44 patients with refractory uveitis associated with Behcet's disease, notable reduction in the frequency of ocular inflammation was noted. However, frequent dosing was required to maintain the outcomes over a 5-year follow-up. The common side effects of the treatment reported are headache, abdominal pain, rash, pneumonia, urinary tract infections, and reactivation of latent TB.

**Etanercept**

Etanercept is a dimeric protein composed of TNF receptor2 and IgGFc fragment. It inhibits both TNFα and TNFβ, thereby reducing formation of proinflammatory cytokines. Use of etanercept in ocular inflammation debatable, as it can worsen uveitis course or even induce inflammation as a paradoxical effect. Foster et al. have compared the efficacy of etanercept with placebo, which showed failure to reduce the relapses in non-infectious uveitis case.

**Golimumab**

Like adalimumab, golimumab is also a fully humanized monoclonal antibody. Hence the risk of allergic reactions and loss of efficacy are very less. In a case of Bechet’s disease who was refractory to TNF-α blocker, reduction in inflammation and sustained remission was noted with the use of golimumab. Authors have reported effective control of inflammation in refractory juvenile idiopathic arthritis-associated uveitis. In a multicenter study of patients with ankylosing spondylitis-associated uveitis, reduction in the rate of uveitis recurrence and disease activity was noted with golimumab.

**Cetrolizumab**

Cetrolizumab is a PEGylated humanized monoclonal antibody. There are limited studies on the efficacy of cetrolizumab in uveitis. Favorable results have been noted in rheumatoid arthritis, spondyloarthropathies, and Crohn’s disease.

**2. Anti-interleukin therapies**

Interleukin IL-1β is a pro-inflammatory cytokine produced by the wide range of cells. Authors have found the role of IL-1β, IL-2, and IL-6 in autoinflammatory and autoimmune conditions. Increased levels of interleukin are noted in aqueous humour, correlating with the disease severity. Anti-interleukins drugs act against preventing the production of additional cytokines and pro-inflammatory molecules.

**Anakinra**

Binding of anakinra with ligands, a pro-inflammatory cytokine, prevents the mediated inflammation. In a study
Table 1: various types of biologics, their specific targets, route of administration, dosage, and side effects

| Generic names | Specific targets | Route     | Dosage                                                                 | Description                                                                 |
|---------------|-----------------|-----------|------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| **TNF- inhibitors** |                 |           |                                                                       |                                                                            |
| Adalimumab    | TNF- α          | SC, IV    | Initial dosage of 80 mg followed by 40 mg in subsequent weeks          | Allergic reactions, headache, malignancy, thrombolytic events, congestive heart failure, reactivation of TB |
|               |                 |           | 0.03 mL (1.5 mg) at baseline, 2 weeks and once at a month for subsequent seven months |                                                                             |
| Infliximab    | TNF- α          | IV, SC    | 3-5 mg at baseline, 2nd and 6th week and every 4-8 weeks              | Headache, abdominal pain, rash, pneumonia, urinary tract infection, reactivation of TB |
|               |                 |           | 1 mg/0.05 ml 6 weeks apart                                             |                                                                             |
| Etanercept    | TNF α and TNF β| SC        | 0.4 mg/kg twice a week                                                | Rashes, diarrhea, infection                                                 |
| Golimumab     | TNF- α          | SC        | 50 mg per month                                                       | ANA positivity, development of infections                                   |
| Certolizumab  | TNF- α          | SC        | 400 mg every week                                                     | Nausea, infections                                                         |
| **Anti-interleukin therapy** |                 |           |                                                                       |                                                                            |
| Anakinra      | IL receptor     | SC        | 100 mg/day                                                            | Headache, vomiting                                                         |
|               |                 |           |                                                                       | Antibody development, allergic reactions, fever, nasopharyngitis           |
| Abatacept     | T cells (CTLA-4)| IV, SC    | 0.5-1g at loading, 1.25g SQ weekly in RA                              | Headache, nausea, Nasopharyngitis, infections                               |
|               |                 |           | 0.1g to max of 1 g IV at baseline, 2nd and 6th                        |                                                                             |
| Rituximab     | B cells (CD20)  | IV, SC    | 375 mg/m² at 4 week intervals or 1,000 g/infusion 2 weeks apart. third dose interval is variable according to the disease severity | Cardiovascular, fatigue, pruritis, nausea, urinary tract infections, antibody development, pulmonary disease |
|               |                 |           | 1mg/0.1ml monthly                                                     |                                                                             |
| **Interferons** | No specific target | SC    | 3-6 million units daily with slow taper                               | Headache, fever, flu- like syndrome, hematological toxicity, elevated liver enzymes, depression, infections, fever, malignancy, arthritis, and thrombocytopenia |
| **Fusion protein of CTLA-4** |                 |           |                                                                       |                                                                            |
| Canakinumab   | IL-1 β          | IV, SC    | 150 mg for 6 weeks                                                   | Headache, vertigo, obesity, diarrhoea, musculoskeletal pain, skin reactions, nasopharyngitis |
| Gevokizumab   | IL-1 β          | IV, SC    | 60 mg every                                                           | Infections, hypersensitivity                                               |
| Tocilizumab   | IL-6R           | IV        | Initially 4 mg/kg once at every 4 weeks                              | Increased serum cholesterol, alanine, aminotransferase levels, injection site reaction |
| Secukinumab   | IL-17A          | IV        | 300 mg/kg                                                             | Headache, infections, gastrointestinal complications, hypercholesterolemia |
| Ustekinumab   | Anti-IL-12 and IL-23 | SC | 45 mg at weeks 0 and 4 and every 12 weeks                           | ANA positivity, infections, nasopharyngitis                                |
| Alemtuzumab   | Anti-CD52       | IV        | 30 mg, thrice a week for 12 months                                   | Headache, skin rashes, nausea, urinary tract, lymphocytopenia, thyroid disease, infusion related reaction, fever, nasopharyngitis |
of nine patients who were treated with anakinra, including those having Behcet’s disease refractory to TNF-α inhibitors, eight patients showed a complete resolution without any adverse effects.\textsuperscript{45} Successful outcome was seen in patients with rheumatoid arthritis, chronic infantile neurological cutaneous articular syndrome, and cryopyrin-associated periodic syndrome.\textsuperscript{46,47} Adverse effects include pneumonia and cellulitis.\textsuperscript{10}

Abatacept
Abatacept is a fusion protein composed of cytotoxic T-lymphocyte antigen 4 molecule to a fragment of human immunoglobulin.\textsuperscript{6} It inhibits the activation T lymphocytes by blocking CD28 and CD80/CD86 receptors.\textsuperscript{48} A multicenter study done in patients with JIA-related uveitis used abatacept as first-line or second-line therapy showing a comparable improvement. In another report a 6-year-old child with JIA-associated uveitis, the use of abatacept showed a clinical improvement.\textsuperscript{49}

Rituximab
Rituximab is a chimeric monoclonal antibody directed against the activation of B-cell production.\textsuperscript{6} A patient with retinal vasculitis who was resistant to conventional therapy was treated with rituximab and disease remission lasting up to 24 months was noted.\textsuperscript{50} In a single-blinded study of patients with retinal vasulitis resistant to cytotoxic drugs, patients were randomized to receive either two courses of rituximab at a dose of 1000 mg twice a month along with oral prednesolone (0.5 mg/kg/day) and methotrexate (15 mg/week) or combination of cyclophosphamide (1000 mg/month), azathioprine (2-3 mg/kg/day), and prednesolone (0.5 mg/kg/day). Patients in rituximab treatment arm showed a significant improvement when compared to the other treatment arm. However, there was no statistically significant improvement in retinal vasculitis in both the arms. The side effects developed during the study period were conjunctivitis, pneumonia, and herpes zoster infection.\textsuperscript{51} Possible side effects are fever, rash, respiratory symptoms, and hypertension.\textsuperscript{10}

3. Interferons
Interferons are a group of cytokines in which type 1 includes IFNα and IFNβ and type II includes IFN-γ.\textsuperscript{6} The immunoregulatory and immunosuppressive effects were found to be beneficial in the treatment of uveitis.\textsuperscript{52} IFNα-2A and IFN α-2B are the two types of human recombinant IFNs produced by Escherichia coli by recombinant deoxyribonucleic acid technology. Half-life of the molecule has been increased in pegylated IFNs allowing longer duration of activity.\textsuperscript{6,10} Hatemi et al. have shown complete/partial remission of active disease in 94% of Behcet’s disease associated-uveitis patients who were treated with interferon.\textsuperscript{53} Other than Behcet’s disease, interferon was found to be helpful in the management of sympathetic ophthalmia, Vogt-Koyanagi-Harda syndrome, birdshot chorioretinopathy, and serpiginous choroiditis.\textsuperscript{54,10} Butler et al. have reported the efficacy of interferon in refractory uveitic cystoid macular edema.\textsuperscript{55} The side effects of interferons are headache, fever, flu-like syndrome, hematological toxicity, elevated liver enzymes, and depression (Fig. 1).\textsuperscript{56}

4. Fusion protein of CTLA-4
It is a new alternative tool that should be attempted when the conventional immunosuppressives and anti-TNF-α agents are ineffective.\textsuperscript{57-58} Authors have reported its effectiveness in the management of severe uveitic cases.\textsuperscript{7, 57-65} Interleukin (IL)-1 has shown to be a key proinflammatory cytokine in many autoimmune diseases and its inhibition might have a promising future among other novel therapeutic opportunities.\textsuperscript{58}

Canakinumab
Canakinumab is human monoclonal antibody acting against IL-1β.\textsuperscript{57} In a report of 16-year-old female with a diagnosis of severe bilateral pan uveitis with retinal vasculitis refractory to other conventional therapies, a single subcutaneous injection of 150 mg canakinumab showed complete resolution of uveitis. The treatment effect lasted for 8 weeks.\textsuperscript{58} A study to find the efficacy of canakinumab and anakinra in Bechet’s disease concluded that canakinumab is successful in the management.\textsuperscript{59} Canakinumab has been found to be effective in controlling recurrences and decreasing the chances of retinal vessel involvement in Bechet’s disease.\textsuperscript{60} Successful management has been reported in patients with JIA-related uveitis also.\textsuperscript{61}

Gevokizumab
Gevokizumab is a monoclonal antibody that reduces the binding affinity of IL-1β. Gul et al. have investigated the safety, pharmacokinetics and clinical efficacy of gevokizumab in seven patients with acute posterior or panuveitis, and/or retinal vasculitis, resistant to azathioprine and/or ciclosporin, and receiving 10 mg/day or less of prednisolone. A single infusion of gevokizumab 0.3 mg/kg was administered in all patients. Rapid onset and sustained reduction in ocular inflammation was noted in four patients in median time of 14 days.\textsuperscript{62} Acute ocular exacerbations were well controlled.
without the need for corticosteroids in patients with Behcet's disease-associated uveitis.\textsuperscript{63} Adverse effects include infections and hypersensitivity reactions.\textsuperscript{64}

**Tocilizumab**

Tocilizumab (myeloma receptor) is a recombinant IgG, which binds with IL-6 receptors and limits the expression of cytokines. In a retrospective study, tocilizumab effectively reduced the central foveal thickness in refractory CME. However, relapses were observed within 3 months after discontinuation of treatment.\textsuperscript{65} Tocilizumab was useful in the management of JIA-related arthritis.\textsuperscript{66} In a prospective study that included 25 patients of JIA, reduction in ocular inflammation was noted in 88.2\% of cases with the use of tocilizumab.\textsuperscript{67} Tocilizumab was successful in the treatment of rheumatoid arthritis. The common side effects include infections and hypersensitivity.\textsuperscript{7}

**Secukinumab**

Secukinumab is a fully humanized monoclonal antibody targeting IL-17A. Increased level of IL-17A has been found in the serum of patients with uveitis and immune-mediated systemic conditions like Vogt-Koyanagi-Harada syndrome and Behcet's disease.\textsuperscript{68,69} A randomized trial study was conducted to explore the efficacy and safety of secukinumab at different dosage versus placebo in the management of non-infectious uveitis. Interim data analysis showed no significant difference between the groups in terms of recurrences.\textsuperscript{70} Secukinumab has been proven to be effective in the treatment of anterior and posterior uveitis patients.\textsuperscript{71}

**Ustekinumab**

Ustekinumab is a monoclonal antibody that specifically binds with the IL-12 and IL23 cytokines. It was found to be effective in alleviating inflammation in Crohn's disease.\textsuperscript{72} In a patient with Behcet's disease, uveitis was successfully treated with ustekinumab.\textsuperscript{73}

**Alemtuzumab**

Alemtuzumab acts against the cell surface CD52. Its effectiveness in various systemic autoinflammatory conditions (lymphocytic leukemia, multiple sclerosis, and rheumatoid arthritis) has been proven by many studies.\textsuperscript{74} An indirect data analysis has reported the use of alemtuzumab in Behcet's-related uveitis. Out of four patients, complete remission was seen in 2 patients and partial remission in 2 patients after 6 months of treatment.\textsuperscript{75}

**Intravitreal injections of biologic agents in uveitis**

Many studies have proven that intravitreal administration of drugs in uveitis is effective in reducing systemic side effects and improved inflammatory control.\textsuperscript{76} Infliximab is a biological agent commonly used to treat many systemic autoimmune disease such as rheumatoid arthritis, inflammatory bowel disease, spondyloarthropathy and psoriasis.\textsuperscript{3,6,10} The side effects of infliximab are well established.\textsuperscript{3} A prospective, noncomparative, pilot study evaluated the effect of single intravitreal injection of infliximab (1 mg/0.05 ml) in 15 eyes with sight threatening relapsing uveitis in Behçet's disease. A significant improvement in BCVA by day 7 was noted, which maintained during the follow up period of 30 days.
However, persistent CME was noted in 80% of the eyes. No ocular or systemic side effects were documented during the study. Intravitreal infliximab of 1 mg/0.05ml was found to be rapid and safe, which can be used in cases contradicted to systemic route of administration. Hamam et al. have conducted a nonrandomized prospective open labelled study to evaluate the short-term efficacy of intravitreal adalimumab (IVA) in active non-infectious uveitis. They reported injection of adalimumab 0.03 ml (1.5mg) intravitreally at baseline, reinjection in an interval of 2 weeks and once at a month for subsequent 7 months was effective in controlling the inflammation, and decreasing the macular edema. Improvement in the best corrected visual acuity was noted in the majority of the cases.

Points to remember while prescribing biologics
1. A complete systemic evaluation by a general physician is important to rule out any congestive heart failure, demyelinating diseases, malignancies, and infections.
2. Laboratory investigations:
   Hematological analysis should be done before initiation of biologics and at the interval of 3 months while patients are on biologics.
   - Liver and renal function tests including serum electrolytes, and glucose should be performed before starting therapy, and every 3-6 months while on treatment.
   - TB skin test, QuantiFERON-TB gold or chest X-ray should be done annually in patients receiving biologic therapy
   - HIV and hepatitis B and C before starting the therapy
3. Patients on anti-TNF therapy should be prepared to receive pneumococcal, influenza, and hepatitis B vaccines. It is contradicted to have live virus vaccines in patients started with anti-TNF therapy.

Conclusion
Biologics have emerged as a new weapon in the armamentarium of managing uveitis. However, there is limited literature evidence to corroborate the study findings on various drugs. The drugs are relatively costly and a complete work-up is needed before starting a biologic therapy.

Competing interests
The authors declare that they have no competing interests.

Citation
Magesan K, Shah A, Biswas J. Biologics In uveitis: An update. IJIR.
DS. Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine. 2016;375:932-43.

16. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS. Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine. 2016;375:932-43.

17. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA. Adalimumab for prevention of uveitis flare in patients with inactive non-infectious uveits controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet. 2016;388:1183-92.

18. Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, Pasadhika S, Lee ST, de Saint Sadors A, Butler NJ, Tessler HH. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. British Journal of Ophthalmology. 2013;97:481-6.

19. Rudwaleit M, Radevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Annals of the rheumatic diseases. 2009;68:696-701.

20. van Denderen JC, Visman IM, Nurmohamed MT, Suttrop-Schulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. The Journal of rheumatology. 2014;41:1843-8.

21. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe's Archive for Clinical and Experimental Ophthalmology. 2012;250:713-20.

22. Bawazeer A, Raffa LH, Nizamuddin. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocular immunology and inflammation. 2010;18:226-32.

23. Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. New England Journal of Medicine. 2017;376:1637-46.

24. Scheinfeld N. Adalimumab: a review of side effects. Expert opinion on drug safety. 2005;4:637-41.

25. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Archives of Ophthalmology. 2005;123:903-12.

26. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet’s disease: a comparative 4-week study. Rheumatology. 2010 Nov 20;50:593-7.

27. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behcet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behceht disease. Archives of Ophthalmology. 2012;130:592-8.

28. Ueda S, Akahoshi M, Takeda A, Inoue Y, Omo K, Ayano M, Kimito Y, Mitoma H, Arinobu Y, Niio H, Tsukamoto H. Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet’s disease. European journal of rheumatology. 2018;5:9.

29. Scott L J. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74:1379-410.

30. Brito-Zerón P, Perez-Alvarez R, Ramos-Casals M, BIOGEAS Study Group. Etanercept and uveits: friends or foes?.

31. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-α Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment. Current eye research. 2010;35:751-6.

32. Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, Wendling D, Lioté F. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. The Journal of rheumatology. 2012;39:233-9.

33. Fonollola A, Artaraz J, Les I, Martinez-Berrothoa A, Izquierdo JP, Lopez AS, Gardeazaba J, Berasategui B, Martinez-Alday N. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocular immunology and inflammation. 2012;20:44-8.

34. Foster CS, Tufail F, Waheed NK, Chu D, Misericocchi E, Baltatzis S, Vredeveld CM. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Archives of ophthalmology. 2003;121:437-40.

35. Tahir Z, Kavanaugh A. The role of golimumab in inflammatory arthritis. A review of the evidence. Therapeutic advances in musculoskeletal disease. 2018;18:191-4.

36. Mesquida M, Victoria Hernandez M, Liorenç V, Pelegrín L, Espinosa G, Dick AD, Adán A. Behçet disease-associated uveitis successfully treated with golimumab. Ocular immunology and inflammation. 2013;21:160-2.

37. William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. Journal of ophthalmic inflammation and infection. 2012;2:231-3.

38. van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AHG, Griep EN, Koehorst CB, Kok MR, Schilder AM, Verhoeof M, van der Horst-Bruinsma IE. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab—The GO-EASY Study. The Journal of rheumatology. 2019;46:153-9.

39. Biggioggero M, Cotti C, Becciolini A, Misericocchi E, Favalli EG. The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. BioMed research international. 2018.

40. Connock M, Tubeuf S, Malottki K, Utthman A, Round J, Bayliss S, Meads C, Moore D. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. Health Technol Assess. 2010;14:1-0.

41. Ferrante M, Vermeire S, Rutgeerts P. Certolizumab pegol in the treatment of Crohn’s disease. Expert opinion on biological therapy. 2013;13:595-605.

42. Özçimen AA, Dilek K, Bingöl Ü, Sarcaoğlu H, Sarandöl A, Taşkapılıoğlu Ö, Yurtkuran M, Yurtkuran MA, Oral HB. IL-1 cluster gene polymorphisms in Turkish patients with Behçet’s disease. International journal of immunogenetics. 2011;38:295-301.

43. Planck SR, Woods A, Clowers JS, Nicklin MJ, Rosenbaum JT, Rosenzweig HL. Impact of IL-1 signalling on experimental uveitis and arthritis. Annals of the rheumatic diseases. 2012;71:753-60.

44. Ooi KG, Galatowicz G, Calder VL, Lightman SL. Cytokines and chemokines in uveitis—Is there a correlation with clinical phenotype?. Clinical medicine & research. 2006;4:294-309.

45. Cantarini L, Vitale A, Scalini P, Dinarello CA, Rignani D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clinical Rheumatology. 2015;34:1293-301.

46. Ramírez J, Cañete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert opinion on drug safety. 2018;17:727-32.

47. Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. British journal of ophthalmology. 2007;91:263-4.
48. Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology. 2013;52:986-97.

49. Birolo C, Zannin ME, Arsenyeva S, Cimaz R, Miserocchi E, Dubko M, Deslandre CJ, Falcini F, Alessio M, La Torre F, Denisova E. Comparative efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. The Journal of rheumatology. 2016;43:2068-73.

50. Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet’s disease with rituximab. Modern Rheumatology. 2008;18:306.

51. Davatchi F, Shams H, Rezaipoor M, Sadeghi abolhassib, Shahram F, Nadji A, Chamsdavatchi c, Akhlagh M, Faezi T, Naderi N. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single blind control study (pilot study). International Journal of Rheumatic Diseases. 2010;13:246-52.

52. Huber JP, David Farrar J. Regulation of effector and memory T cell functions by type I interferon. Immunology. 2011;132:466-74.

53. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Hourman MH, Kötter I, Olivier I, Salvari R, Sfikakis PP. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Annals of the rheumatic diseases. 2009;68:1528-34.

54. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Lemaître C, Fradeau C, LeHoang P, Piette JC. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. British Journal of Ophthalmology. 2007;91:335-9.

55. Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocular immunology and inflammation. 2012;20:86-90.

56. Steijger S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharmacy world and science. 2005;27:423.

57. Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, Nar H. One target—two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. Journal of molecular biology. 2013 Jan 9;425:94-111.

58. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet’s disease with syndrome for eye disease. Annals of the Rheumatic Diseases. 2012;71:1589-91.

59. Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Fabiani C, Halder B, Chamberlain AM, Gul A, Hourman MH, Kötter I, Olivier I, Salvari R, Sfikakis PP. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Annals of the rheumatic diseases. 2009;68:1528-34.

60. Toplak N, Blazina Š, Avčin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Design, Development and Therapy. 2018;12:1633.

61. Güll A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Annals of the rheumatic diseases. 2012;71:563-6.

62. Tugal-Tutkun I, Kadayifcilar S, Khairallah M, Lee SC, Ozdal P, Özyazgan Y, Song JH, Yu HG, Lehner V, de Cordoue A, Bernard O. Safety and efficacy of gevokizumab in patients with Behcet’s disease uveitis: results of an exploratory phase 2 study. Ocular immunology and inflammation. 2017;25:62-70.

63. Zhou Y, Chen SL, Shen N, Lu Y. Cytokines and Behcet’s disease. Autoimmunity reviews. 2012;11:699-704.

64. Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, de la Maza MS, Adán A. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361-70.

65. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umeyabashi H, Murata T, Miyoshi M, Tomita M. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. The Lancet. 2008;371:998-1006.

66. Calvo Río V, Santos Gómez M, Calvo I, González- Fernández MI, López Montesinos B, Mesquida M, Adán A, Hernández MV, Maiz O, Atanes A, Bravo B. Anti–Interleukin 6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis & Rheumatology. 2017;69:668-75.

67. Kollos JK, Lindén A. Interleukin-17 family members and inflammation. Immunology. 2004;21:467-76.

68. Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cellular & molecular immunology. 2010;7:164.

69. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Liew SM, Bezybak V, Androudi S. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777-87.

70. Sota J, Rigante D, Lopalco G, Frediani B, Franceschini R, Galeazzi M, Iannone F, Tosi GM, Fabiani C, Cantarini L. Biological therapies for the treatment of Behcet’s disease-related uveits beyond TNF-alpha blockade: a narrative review. Rheumatology international. 2018;38:25-35.

71. Lamb YN, Duggan ST. Ustekinumab: a review in moderate to severe Crohn’s disease. Drugs. 2017;77:1105-14.

72. Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martin L, Atteno M. Biological treatments in Behcet’s disease: beyond anti-TNF therapy. Mediators of inflammation. 2014.

73. Riera R, Porfirio GJ, Torloni MR. Alectuzumab for multiple sclerosis. Cochrane Database of Systematic Reviews. 2016.

74. Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics: targets & therapy. 2014; 8:67.

75. Yap YC, Papathomas TJ, Kamil A. Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in non infectious posterior uveitis. Int J Ophthalmol 2015;8:835-8

76. Markomichelakis N, Delica E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight threatening relapsing uveitis in Behcet disease: A pilot study in 15 patients. Am J Ophthalmol 2012;154:534 41

77. Hamza MM, Macky TA, Siddky MK, Ragab G, Soliman MM. INTRAVITREAL INFlixIMAB IN REFRACTORY UVEITIS IN BEHCET’S DISEASE: A Safety and Efficacy Clinical Study. Retina. 2016;36:2399-408.

78. Hamam RN, Bankian AW, Antonios RS, Abdulaa MR, Alameddine RM, El Mollayess G, Mansour AM. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocular immunology and inflammation. 2016 May 3;24(3):319-26.

79. Gallego-Pinazo R, Dolz-Marco R, Martínez-Castillo S, Fernandez Arevalo J, Díaz-Llopis M. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflammation & Allergy-Drug Targets. 2013;12:38-45.